TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18379232

Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg every 8 hrs via a 4‐hr intravenous infusion
Number of subjects: 531

Group type: COMPARATOR
Intervention: Imipenem 500 mg every 6 hrs or 1000 mg every 8 hrs via 30‐ or 60‐min intravenous infusions
Number of subjects: 531

Group type: EXPERIMENTAL
Intervention: Doripenem for patients with Pseudomonas aeruginosa
Number of subjects: 531

Group type: COMPARATOR
Intervention: Imipenem for patients with Pseudomonas aeruginosa
Number of subjects: 531

Group type: COMPARATOR
Intervention: Doripenem vs Imipenem
Number of subjects: 531
Study: 16635650

Group type: EXPERIMENTAL
Intervention: 35% CO2/65% O2 mixture
Number of subjects: 91

Group type: COMPARATOR
Intervention: Atmospheric compressed air
Number of subjects: 91
Study: 12789182

Group type: EXPERIMENTAL
Intervention: Dermasanding treatment
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (unsanded side)
Number of subjects: 15
Study: 10663454

Group type: EXPERIMENTAL
Intervention: MDL 100,240 2.5 mg orally, q.d. for 8 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MDL 100,240 10 mg orally, q.d. for 8 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MDL 100,240 20 mg orally, q.d. for 8 days
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: MDL 100,240 (oral solution)
Number of subjects: 12
Study: 8801396

Group type: EXPERIMENTAL
Intervention: Lovastatin (20-80 mg/day)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Gemfibrozil (600 mg b.i.d.)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Lovastatin + cholestyramine
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Gemfibrozil + cholestyramine
Number of subjects: 59
Study: 1906434

Group type: EXPERIMENTAL
Intervention: metoprolol OROS 21/285
Number of subjects: 53

Group type: COMPARATOR
Intervention: atenolol 100 mg
Number of subjects: 53
Study: 6849734

Group type: EXPERIMENTAL
Intervention: Bedtime chenic acid 8 mg kg‐1 day‐1
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Sodium acetyl salicylate 600 mg four times daily
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Bedtime chenic acid 8 mg kg‐1 day‐1 plus sodium acetyl salicylate
Number of subjects: 7

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 7
Study: 31399378

Group type: EXPERIMENTAL
Intervention: Inactivated varicella zoster virus vaccine (VZV)
Number of subjects: 5286

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5286
Study: 28544704

Group type: EXPERIMENTAL
Intervention: Treat-to-target
Number of subjects: 532

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 532
Study: 27749141

Group type: EXPERIMENTAL
Intervention: Combination of haloperidol and midazolam
Number of subjects: 195

Group type: COMPARATOR
Intervention: Haloperidol alone
Number of subjects: 195
Study: 24782093

Group type: EXPERIMENTAL
Intervention: Azithromycin combined with paclitaxel and cisplatin (ATP)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Paclitaxel and cisplatin (TP)
Number of subjects: 86
Study: 22779281

Group type: EXPERIMENTAL
Intervention: Oral-B Precision Clean (PC) brush head
Number of subjects: 267

Group type: COMPARATOR
Intervention: Store Brand Easyflex (SB) brush head
Number of subjects: 267

Group type: COMPARATOR
Intervention: Laboratory cleaning efficacy test using worn brush heads
Number of subjects: 267
Study: 21058476

Group type: EXPERIMENTAL
Intervention: Catgut implantation
Number of subjects: 74

Group type: COMPARATOR
Intervention: Fenofibrate
Number of subjects: 74
Study: 17929519

Group type: EXPERIMENTAL
Intervention: Delayed loading (4 months after implant insertion)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Early loading (1 week after implant surgery)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Immediate loading (day of or day after surgery)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison between loading times)
Number of subjects: 30
Study: 15711660

Group type: EXPERIMENTAL
Intervention: High intra-abdominal pressure
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Low intra-abdominal pressure
Number of subjects: 22
Study: 11257249

Group type: EXPERIMENTAL
Intervention: 30 mg weekly
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30 mg twice a week
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30 mg twice a week for 12 weeks followed by 30 mg weekly
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 30 mg twice a week for 6 weeks followed by 30 mg weekly
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 60 mg weekly
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Single 60 mg loading dose followed by 30 mg weekly doses
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 60 mg weekly (Dosage regimen VI)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 30 mg twice a week for 12 weeks (Dosage regimen III)
Number of subjects: 60
Study: 9886194

Group type: EXPERIMENTAL
Intervention: Artesunate (2mg/kg/day for five days, then 1 mg/kg/day for two days: total=12 mg/kg)
Number of subjects: 443

Group type: COMPARATOR
Intervention: Artemether (4 mg/kg followed by 2 mg/kg/day for two days, then 1 mg/kg/day for four days: total=12 mg/kg)
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Artesunate
Number of subjects: 443

Group type: COMPARATOR
Intervention: Artemether
Number of subjects: 443

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 443
Study: 8002848

Group type: EXPERIMENTAL
Intervention: Drug intervention to lower cholesterol levels
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lipid intervention
Number of subjects: 0
Study: 2534822

Group type: EXPERIMENTAL
Intervention: Chlormezanone
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Flunitrazepam
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 7698136

Group type: EXPERIMENTAL
Intervention: Ramipril (titrated from 1.25 mg to a maximum of 10 mg once daily over 4 weeks, mean dose 8 mg)
Number of subjects: 223

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Ramipril
Number of subjects: 223
Study: 699938

Group type: EXPERIMENTAL
Intervention: Intravenous practolol 15 mg followed by oral practolol 200 mg at 12 h intervals
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Intravenous practolol
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 94
Study: 31820551

Group type: EXPERIMENTAL
Intervention: RLP+ (Reproductive Life Planning with contraceptive action planning)
Number of subjects: 984

Group type: EXPERIMENTAL
Intervention: RLP (Reproductive Life Planning)
Number of subjects: 984

Group type: COMPARATOR
Intervention: Information only (Control group)
Number of subjects: 984
Study: 27716513

Group type: EXPERIMENTAL
Intervention: Chamomile extract
Number of subjects: 0
Study: 24395083

Group type: EXPERIMENTAL
Intervention: reading intervention (50 minutes a day in small groups)
Number of subjects: 0

Group type: COMPARATOR
Intervention: business as usual (BAU) condition
Number of subjects: 0
Study: 23838912

Group type: EXPERIMENTAL
Intervention: Early postoperative enteral immunonutrition (formula supplemented with arginine, omega‐3 fatty acids and RNA)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Isocaloric-isonitrogenous control
Number of subjects: 109
Study: 22436475

Group type: EXPERIMENTAL
Intervention: Intra-articular lidocaine (IAL) - 4 mg/kg (up to 200 mg) of 1% lidocaine injected into the glenohumeral joint.
Number of subjects: 44

Group type: COMPARATOR
Intervention: Intravenous sedation (IVS) - medications for sedation as per physician discretion.
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Both groups (IAL and IVS).
Number of subjects: 44
Study: 19018157

Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS) 50 mg weekly
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 17588424

Group type: EXPERIMENTAL
Intervention: Spyder aortic connector
Number of subjects: 22

Group type: COMPARATOR
Intervention: Hand-sewn technique
Number of subjects: 22
Study: 15450562

Group type: EXPERIMENTAL
Intervention: T(3) 125 microg/day orally for 7 days preoperatively and from the first postoperative day till discharge
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study: 11842271

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate supplementation (5-day load of 0.3 g/kg(-1) x day(-1) followed by a 5-week maintenance dose of 0.03 g/kg(-1) x day(-1))
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate supplementation (5-week maintenance dose)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Creatine monohydrate supplementation
Number of subjects: 22
Study: 9788454

Group type: EXPERIMENTAL
Intervention: Ramipril (1.25 to 5.00 mg/day)
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo plus conventional antihypertensive therapy
Number of subjects: 97
Study: 8002083

Group type: EXPERIMENTAL
Intervention: Erythromycin treatment
Number of subjects: 34

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 34
Study: 2969551

Group type: EXPERIMENTAL
Intervention: Heparin therapy combined with anti-thrombosis stockings
Number of subjects: 286

Group type: COMPARATOR
Intervention: Heparin therapy alone
Number of subjects: 286
Study: 31226238

Group type: EXPERIMENTAL
Intervention: Bioabsorbable implant (Latera)
Number of subjects: 137
Study: 27821639

Group type: EXPERIMENTAL
Intervention: Percutaneous mastoid electrical stimulator (PMES)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PMES
Number of subjects: 0
Study: 25029005

Group type: EXPERIMENTAL
Intervention: Caffeine 5 mg.kg of body mass
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Caffeine 10 mg.kg of body mass
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo (0 mg.kg of body mass)
Number of subjects: 13
Study: 23494615

Group type: EXPERIMENTAL
Intervention: Brain-machine interface (BMI) training
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (sham group)
Number of subjects: 32
Study: 21510785

Group type: EXPERIMENTAL
Intervention: Confirmed awareness of campaign advertising
Number of subjects: 5616
Study: 19620845

Group type: EXPERIMENTAL
Intervention: Milnacipran
Number of subjects: 0
Study: 16965211

Group type: EXPERIMENTAL
Intervention: Interpersonal Counseling (IPC)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 19
Study: 15237655

Group type: EXPERIMENTAL
Intervention: Human albumin (300 ml per day for 72 hours)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: HES 500 ml (per day for 72 hours)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: HES 1000 ml (per day for 72 hours)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Normal saline (1000 ml per day for 72 hours)
Number of subjects: 61
Study: 11236257

Group type: EXPERIMENTAL
Intervention: Group I (40 patients with stabilized UA after pharmacological treatment)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Group II (14 patients with significant cardiac events during hospitalization)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Patients who died during hospitalization
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control group (25 healthy subjects)
Number of subjects: 54
Study: 8800298

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment (50, 10, 2, 0.4 micrograms/g)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: Calcipotriol ointment
Number of subjects: 168

Group type: COMPARATOR
Intervention: Ointment vehicle
Number of subjects: 168
Study: 1735081

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU, 700 mg/m2/d), folinic acid (FA, 300 mg/m2/d), and oxaliplatin (l-OHP, 25 mg/m2/d) infused continuously for 5 days every 3 weeks, modulated sinusoidally over 24 hours.
Number of subjects: 93

Group type: COMPARATOR
Intervention: Infusion rate modulated according to circadian rhythms.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: 5-fluorouracil (5-FU, 700 mg/m2/d), folinic acid (FA, 300 mg/m2/d), and oxaliplatin (l-OHP, 25 mg/m2/d) infused continuously for 5 days every 3 weeks.
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Patients with good performance status (PS, 0 or 1, by WHO criteria).
Number of subjects: 93
Study: 3883700

Group type: EXPERIMENTAL
Intervention: Antacid treatment (10 ml of an antacid suspension seven times a day, buffering 367.5 mmol acid)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Antacid treatment
Number of subjects: 100
Study: 28699045

Group type: EXPERIMENTAL
Intervention: Standard curriculum plus nutrition education for preschoolers (Group A)
Number of subjects: 164

Group type: EXPERIMENTAL
Intervention: Standard curriculum plus nutrition education for preschoolers and their caregivers (Group B)
Number of subjects: 164

Group type: COMPARATOR
Intervention: Standard curriculum (Control Group)
Number of subjects: 164
Study: 28739263

Group type: EXPERIMENTAL
Intervention: Subcutaneous ketamine (0.1, 0.2, 0.3, 0.4, and 0.5 mg/kg)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Midazolam (active control)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Repeated treatments of subcutaneous ketamine
Number of subjects: 16
Study: 25059750

Group type: EXPERIMENTAL
Intervention: Approach-avoidance task
Number of subjects: 284

Group type: EXPERIMENTAL
Intervention: Approach-avoidance task + anti-smoking PSA
Number of subjects: 284

Group type: COMPARATOR
Intervention: Control version of approach-avoidance task + control PSA
Number of subjects: 284
Study: 24192334

Group type: EXPERIMENTAL
Intervention: Apixaban
Number of subjects: 18201

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 18201
Study: 21406307

Group type: EXPERIMENTAL
Intervention: LoBAG(30) diet (30% carbohydrate, 30% protein, 40% fat)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control diet (15% protein, 55% carbohydrate, 30% fat)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: LoBAG(30) diet
Number of subjects: 8
Study: 18424324

Group type: EXPERIMENTAL
Intervention: D‐dimer measurement and MSCT (DD‐CT strategy, n=903)
Number of subjects: 1819

Group type: EXPERIMENTAL
Intervention: D‐dimer measurement, venous compression ultrasonography of the leg, and MSCT (DD‐US‐CT strategy, n=916)
Number of subjects: 1819

Group type: EXPERIMENTAL
Intervention: D‐dimer measurement, venous compression ultrasonography of the leg, and MSCT (DD‐US‐CT strategy)
Number of subjects: 1819

Group type: EXPERIMENTAL
Intervention: D‐dimer measurement and MSCT (DD‐CT strategy)
Number of subjects: 1819
Study: 16866794

Group type: EXPERIMENTAL
Intervention: Oral misoprostol 25 microg every 3 h (group 1, n = 100)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Oral misoprostol followed by oxytocin (group 2, n = 100)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Oral misoprostol (group 1)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both regimens (group 1 and group 2)
Number of subjects: 200
Study: 14678208

Group type: EXPERIMENTAL
Intervention: 4.0 mg nickel sulfate hexahydrate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 1.0 mg nickel sulfate hexahydrate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 0.3 mg nickel sulfate hexahydrate
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 60
Study: 10520053

Group type: EXPERIMENTAL
Intervention: Birch pollen allergoid immunotherapy (IT) plus symptomatic treatment
Number of subjects: 37

Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 37
Study: 7728484

Group type: EXPERIMENTAL
Intervention: Duplex ultrasound scanning
Number of subjects: 74

Group type: COMPARATOR
Intervention: Venography
Number of subjects: 74
Study: 1822906

Group type: COMPARATOR
Intervention: Praziquantel 50 mg/kg/day for 15 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Albendazole 15 mg/kg/day for 30 days
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Both albendazole and praziquantel
Number of subjects: 100
Study: 6456140

Group type: EXPERIMENTAL
Intervention: Topical erythromycin base 2%
Number of subjects: 69

Group type: COMPARATOR
Intervention: Vehicle/N alone
Number of subjects: 69
Study: 31116355

Group type: EXPERIMENTAL
Intervention: Evolocumab
Number of subjects: 27564

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27564
Study: 26971543

Group type: EXPERIMENTAL
Intervention: Endovascular therapy (ET)
Number of subjects: 98
Study: 25014619

Group type: EXPERIMENTAL
Intervention: Quantitative sensory testing (QST) procedures
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Quality of life (PedsQL) and anxiety and depression scale (RCADS)
Number of subjects: 48
Study: 23519054

Group type: EXPERIMENTAL
Intervention: Herbal mucoadhesive tablets
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo mucoadhesive tablets
Number of subjects: 40

Group type: COMPARATOR
Intervention: Commercial mouthwash
Number of subjects: 40
Study: 21184622

Group type: EXPERIMENTAL
Intervention: Nilotinib 800 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Warfarin 25 mg alone (placebo control)
Number of subjects: 24
Study: 18808378

Group type: EXPERIMENTAL
Intervention: Topical betulin-based oleogel twice daily
Number of subjects: 45

Group type: COMPARATOR
Intervention: Cryotherapy with liquid nitrogen
Number of subjects: 45

Group type: COMPARATOR
Intervention: Combination of cryotherapy with topical betulin-based oleogel
Number of subjects: 45
Study: 17388922

Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Alefacept
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Efalizumab
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 15002062

Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Obese patients (preoperative)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Obese patients (postoperative)
Number of subjects: 22
Study: 11255327

Group type: EXPERIMENTAL
Intervention: Total skin examination performed by a dermatologist on all children.
Number of subjects: 1116
Study: 9702934

Group type: EXPERIMENTAL
Intervention: Losartan 50 mg titrated to losartan 50 mg/hydrochlorothiazide (HCT) 12.5 mg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg titrated to 10 mg
Number of subjects: 20
Study: 9247979

Group type: EXPERIMENTAL
Intervention: Yohimbine
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 1742817

Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms, n = 9)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo (n = 10)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Clonidine (300 micrograms)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 6755789

Group type: EXPERIMENTAL
Intervention: Randomized saphenous vein grafts
Number of subjects: 446

Group type: COMPARATOR
Intervention: Randomized or obligatory PTFE grafts
Number of subjects: 446

Group type: COMPARATOR
Intervention: Obligatory PTFE grafts
Number of subjects: 446
Study: 30650444

Group type: EXPERIMENTAL
Intervention: Obese patients' platelets after weight loss
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Obese patients' platelets before weight loss
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group platelets with SERCA3 inhibition
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Addition of ADP to agonist in obese patients and SERCA3-inhibited control platelets
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: SERCA3 expression in obese patients' platelets
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Thrombin-induced αIIbβ3 activation in obese patients' platelets
Number of subjects: 40
Study: 27990692

Group type: EXPERIMENTAL
Intervention: CXP (creos xenoprotect)
Number of subjects: 49

Group type: COMPARATOR
Intervention: BG (reference membrane)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: CXP
Number of subjects: 49

Group type: COMPARATOR
Intervention: BG
Number of subjects: 49
Study: 25388143

Group type: EXPERIMENTAL
Intervention: Self-help training program
Number of subjects: 34

Group type: COMPARATOR
Intervention: Active control group (general cognitive stimulation activities)
Number of subjects: 34
Study: 24278467

Group type: EXPERIMENTAL
Intervention: Bed Rest (BR)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Sitting Control (SC)
Number of subjects: 28
Study: 21073363

Group type: EXPERIMENTAL
Intervention: Eplerenone (up to 50 mg daily)
Number of subjects: 2737

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2737
Study: 18341017

Group type: EXPERIMENTAL
Intervention: ROM (rifampicin, ofloxacin, and minocycline) administered by body weight to adults above 15 years; RMP (rifampicin) administered by body weight to children below 15 years.
Number of subjects: 300

Group type: COMPARATOR
Intervention: Vitamins administered to non-treated group.
Number of subjects: 300
Study: 16818928

Group type: EXPERIMENTAL
Intervention: Cysticidal drug therapy
Number of subjects: 942
Study: 14505199

Group type: EXPERIMENTAL
Intervention: Transmeatal cochlear laser treatment (TCL) using diode lasers (lambda=635 nm, 7.8 mW cw, n=17 and lambda=830 nm, 20 mW cw, n=18) with a space irradiation of 4 J/cm2 at the site of maximal cochlear injury.
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Transmeatal cochlear laser treatment (TCL)
Number of subjects: 35
Study: 11121366

Group type: EXPERIMENTAL
Intervention: Green tea chew candies containing green tea extracts (n = 22: 11 males, 11 females)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo chew candies without active substances (n = 25: 12 males, 13 females)
Number of subjects: 47
Study: 8896853

Group type: EXPERIMENTAL
Intervention: 1.3 MAC sevoflurane/N2O anaesthesia (n = 10)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Equi‐MAC isoflurane/N2O anaesthesia (n = 11)
Number of subjects: 21
Study: 1810328

Group type: EXPERIMENTAL
Intervention: Conventional composite core build‐up paste
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluoridated core build‐up paste
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Glass cermet
Number of subjects: 30

Group type: COMPARATOR
Intervention: Non-fluoridated product (Group 1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Fluoridated products (Group 2 and Group 3)
Number of subjects: 30
Study: 6864076

Group type: EXPERIMENTAL
Intervention: Iron therapy for 2 weeks
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (normal iron status)
Number of subjects: 15